D. Keith Grossman - 03 Jun 2024 Form 4 Insider Report for Outset Medical, Inc. (OM)

Role
Director
Signature
By: John L Brottem For: D Keith Grossman
Issuer symbol
OM
Transactions as of
03 Jun 2024
Net transactions value
-$67,308
Form type
4
Filing time
03 Jun 2024, 18:57:25 UTC
Previous filing
29 May 2024
Next filing
05 Sep 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OM Common Stock Options Exercise $34,616 +31,186 +73% $1.11 74,035 03 Jun 2024 Direct F1
transaction OM Common Stock Sale $99,766 -26,230 -35% $3.80 47,805 03 Jun 2024 Direct F1, F2
transaction OM Common Stock Options Exercise $42,310 +38,117 +80% $1.11 85,922 03 Jun 2024 Direct F1
transaction OM Common Stock Sale $44,468 -11,887 -14% $3.74 74,035 03 Jun 2024 Direct F1, F2
holding OM Common Stock 5,186 03 Jun 2024 Grossman Fam Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OM Non-Qualified Stock Option (right to buy) Options Exercise $0 -31,186 -45% $0.000000 38,117 03 Jun 2024 Common Stock 31,186 $1.11 Direct F1, F3
transaction OM Non-Qualified Stock Option (right to buy) Options Exercise $0 -38,117 -100% $0.000000* 0 03 Jun 2024 Common Stock 38,117 $1.11 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were affected pursuant to a Rule 10b51 Trading Plan adopted by the reporting person on August 7, 2023.
F2 The price reported in Column 4 is a weighted average price. The shares of common stock of the Issuer were sold in multiple transactions at prices ranging from $3.66-$3.83. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 This option vested 25% on April 15, 2015 and then in 36 equal monthly installments thereafter.